Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial public offering. While the company didn't specify terms in its SEC filing ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

at an initial public offering price of $18.00 per share, on February 3, 2025. In addition, Metsera today announced the exercise i NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ...

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...